Abstract 7683: A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer

Abstract Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based therapy is the mainstay of treatment, with 70% chance of treatment sensitivity. Resistance to platinum therapy is the leading cause of mortality in advanced ovarian cancer. There are limited studies using proteomics to evaluate platinum resistance in ovarian cancer. This study aims to perform proteomic evaluation of treatment naive tissue from high grade serous ovarian cancer (HGSOC) tumors that are platinum-sensitive (PS) versus resistant (PR). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue collected from 63 patients with HGSOC were analyzed, including 40 PS & 23 PR. Platinum sensitivity was defined as disease response without evidence of recurrence after 6 months of treatment. Samples were analyzed using a high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) protocol. Differential expression (DE) analysis was performed to identify proteins distinguishing between the two groups. Unsupervised machine learning techniques such as least absolute shrinkage and selection operator (LASSO) regression analysis, linear discriminant analysis (LDA), and weighted gene co-expression network analysis (WCGNA) were employed to create a differentially expressed protein profile between PS and PR. Results: Among 4048 proteins identified, 1,604 met quality thresholds for further analysis, appearing in >50% of samples. Thirty-seven proteins were significantly differentially expressed with four upregulated in PS and 33 upregulated in PR. With LASSO regression analysis, an additional 61 DE proteins were identified. LDA revealed 7 proteins (DPM1, INF2, ISYNA1, RBM12B, ATP5F1C, GNL1, UBA7) to have a predictive potential with 85% sensitivity and 100% specificity. Functional enrichment analysis implicated pathways related to RNA binding, epigenetic regulation, spliceosome activity, glutathione metabolism, and metabolic reprogramming in platinum sensitivity. Conclusion: With the combination of traditional statistics and unsupervised machine learning, this study generated a list of DE proteins and facilitated a 7-protein panel that can be used to further investigate and understand the complex tumor dynamics behind platinum sensitivity and resistance. Citation Format: Nujsaubnusi Cassandra Vue, Kyla Frenia, Xi Peng, Eirwen Miller, John Nakayama, Sharon Liang, Sarah Crafton, Alyssa Wield, Christopher Morse, Thomas Krivak, Qiangmin Zheng, Kunhong Xiao. A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7683.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-7683
Primary Topic
Advanced Proteomics Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 7683: A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer

Thomas C. Krivak, Xi Peng, Alyssa Wield, Sarah Crafton et al.
Cancer Research
Advanced Proteomics Techniques and Applications
article

Abstract 7683: A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer

Thomas C. Krivak, Xi Peng, Alyssa Wield, Sarah Crafton, Kunhong Xiao, Kyla Frenia, Nujsaubnusi Vue, Sharon X. Liang, Eirwen M. Miller, Christopher B. Morse, John Nakayama, Qiangmin Zheng
article en

Abstract

Abstract Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based therapy is the mainstay of treatment, with 70% chance of treatment sensitivity. Resistance to platinum therapy is the leading cause of mortality in advanced ovarian cancer. There are limited studies using proteomics to evaluate platinum resistance in ovarian cancer. This study aims to perform proteomic evaluation of treatment naive tissue from high grade serous ovarian cancer (HGSOC) tumors that are platinum-sensitive (PS) versus resistant (PR). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue collected from 63 patients with HGSOC were analyzed, including 40 PS & 23 PR. Platinum sensitivity was defined as disease response without evidence of recurrence after 6 months of treatment. Samples were analyzed using a high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) protocol. Differential expression (DE) analysis was performed to identify proteins distinguishing between the two groups. Unsupervised machine learning techniques such as least absolute shrinkage and selection operator (LASSO) regression analysis, linear discriminant analysis (LDA), and weighted gene co-expression network analysis (WCGNA) were employed to create a differentially expressed protein profile between PS and PR. Results: Among 4048 proteins identified, 1,604 met quality thresholds for further analysis, appearing in >50% of samples. Thirty-seven proteins were significantly differentially expressed with four upregulated in PS and 33 upregulated in PR. With LASSO regression analysis, an additional 61 DE proteins were identified. LDA revealed 7 proteins (DPM1, INF2, ISYNA1, RBM12B, ATP5F1C, GNL1, UBA7) to have a predictive potential with 85% sensitivity and 100% specificity. Functional enrichment analysis implicated pathways related to RNA binding, epigenetic regulation, spliceosome activity, glutathione metabolism, and metabolic reprogramming in platinum sensitivity. Conclusion: With the combination of traditional statistics and unsupervised machine learning, this study generated a list of DE proteins and facilitated a 7-protein panel that can be used to further investigate and understand the complex tumor dynamics behind platinum sensitivity and resistance. Citation Format: Nujsaubnusi Cassandra Vue, Kyla Frenia, Xi Peng, Eirwen Miller, John Nakayama, Sharon Liang, Sarah Crafton, Alyssa Wield, Christopher Morse, Thomas Krivak, Qiangmin Zheng, Kunhong Xiao. A proteomic analysis of differential protein expression between platinum-sensitive and platinum-resistant high grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7683.

Cancer ResearchVol. 86(7_Supplement)
Allegheny Health Network (US), University of Pittsburgh (US), Western Pennsylvania Hospital (US)
Reduced inequalities
Openalex Percentile: Top 8%
Advanced Proteomics Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.